National University of Malaysia   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Bandar Baru Bangi Malaysia (1970)

Organization Overview

First Clinical Trial
2007
NCT00545116
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Anaesthesiologist | DANA IMPAK PERDANA | Department of Medicine, Faculty of Medicine, National University of Malaysia | Department of Neurosurgery, Faculty of Medicine, University Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia | Dr. Liyana Zaharuddin | Faculty of Medicine, National University of Malaysia | Faculty Of Medicine, Universiti Kebangsaan Malaysia | HOSPITAL CANSELOR TUANKU MUHRIZ, UKM (UNIVERSITI KEBANGSAAN MALAYSIA MEDICAL CENTRE) | Hospital Canselor Tuanku Muhriz Universiti Kebangsaan Malaysia (HCTM-UKM) | HOSPITAL CANSELOR TUANKU MUHRIZ, UNIVERSITI KEBANGSAAN MALAYSIA MEDICAL CENTER | Institue of Microengineering and Nanoelectronics (IMEN), Universiti Kebangsaan Malaysia | INSTITUTE OF MICROENGINEERING AND ELECTRONICS (IMEN), UKM | Isa Naina Mohamed | National University Malaysia | National University of Malaysia | norlinah@ppukm.ukm.edu.my | nor zila hassan malek | Pusat Perubatan UKM | Pusat Perubatan Universiti Kebangsaan Malaysia | The National University of Malaysia | UKMMC | Universiti Kebangsaan Malaysia Medical Center | Universiti Kebangsaan Malaysia Medical Centre | Universiti Kebangsaan Malaysia Medical Molecular Biology Institute (UMBI) | Universiti Kenangsaan Malaysia Medical Centre | University Kebangsaan | University Kebangsaan Malaysia Medical Centre

Active Ingredients

Drugs in Phase 4 Trials (19)

ambroxol (1 trial)

colchicine (colbenemid) (1 trial)

dexamethasone (2 trials)

dexmedetomidine (precedex) (1 trial)

empagliflozin (jardiance) (1 trial)

fondaparinux sodium (arixtra) (1 trial)

granisetron (kytril) (2 trials)

ketamine (ketalar) (4 trials)

latanoprost (xalatan) (1 trial)

liraglutide (victoza) (1 trial)

morphine (2 trials)

neuroaid (1 trial)

palonosetron (aloxi) (1 trial)

phenylephrine (Prefrin) (1 trial)

pyridoxine (1 trial)

scopolamine (transderm scop) (1 trial)

stempeucel (2 trials)

timolol (blocadren) (1 trial)

vitamin e (3 trials)

Drugs in Phase 3 Trials (14)

bifidobacterium animalis (1 trial)

cd19 car-t cells (1 trial)

cyclophosphamide (cytoxan) (1 trial)

fludarabine (fludara) (1 trial)

hyaluronic acid (1 trial)

Lactobacillus acidophilus (1 trial)

lactobacillus casei (1 trial)

linagliptin (tradjenta) (2 trials)

meperidine (demerol) (2 trials)

methylcellulose (1 trial)

midazolam (versed) (2 trials)

progesterone (progestasert) (2 trials)

propofol (diprivan) (3 trials)

umbilical cord mesenchymal stem cells (2 trials)

Drugs in Phase 2 Trials (18)

albumin (Human) (Plasbumin) (1 trial)

allogeneic adipose derived mesenchymal stem cell (2 trials)

autologous mesenchymal stem cells (1 trial)

autologous mononuclear stem cell (1 trial)

bone marrow derived mesenchymal stem cells (1 trial)

cefuroxime (zinacef) (1 trial)

dinoprostone (prostin e2) (1 trial)

essential oils (1 trial)

gemeprost (1 trial)

hesperidin (1 trial)

levofloxacin (levaquin) (3 trials)

lidocaine (xylocaine) (3 trials)

moxifloxacin (avelox) (2 trials)

nifedipine (procardia) (1 trial)

oil palm phenolics (2 trials)

povidone-iodine (betadine) (1 trial)

prilocaine (citanest) (2 trials)

umbilical cord serum (1 trial)

Drugs in Phase 1 Trials (4)

dydrogesterone (gynorest) (1 trial)

insulin human (humulin) (1 trial)

maltose (1 trial)

trehalose (2 trials)

Drugs in Other Trials (28)

alteplase (Activase) (2 trials)

benzydamine (1 trial)

carbetocin (Pabal) (1 trial)

clarithromycin (biaxin) (1 trial)

cow milk (1 trial)

dornase alfa (pulmozyme) (2 trials)

esomeprazole (nexium) (1 trial)

fentanyl (Innovar) (1 trial)

glucose (1 trial)

hydrocortisone (solu-cortef) (1 trial)

lactobacillus (1 trial)

lactobacillus delbrueckii (1 trial)

lactobacillus reuteri (1 trial)

lavender (1 trial)

letrozole (femara) (1 trial)

metoclopramide (reglan) (1 trial)

mometasone (elocon) (2 trials)

oryza sativa (1 trial)

oxytocin (syntocinon) (2 trials)

peppermint extract (1 trial)

procaine benzylpenicillin (novocaine) (1 trial)

ropivacaine (naropin) (1 trial)

sitagliptin (januvia) (1 trial)

sodium chloride (1 trial)

soybean (1 trial)

thiamine (1 trial)

tranexamic acid (cyklokapron) (1 trial)

vitamin c (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anastomotic Leak (Phase 2)

Ataxia (Phase 1)

Binge-Eating Disorder (Phase 4)

Bulimia (Phase 4)

Cardiovascular Diseases (Phase 1)

Cerebellar Ataxia (Phase 1)

Constipation (Phase 3)

Diabetic Retinopathy (Phase 4)

Dry Eye Syndromes (Phase 2)

Endophthalmitis (Phase 2)

Fistula (Phase 2)

Gastroparesis (Phase 2)

Glaucoma (Phase 4)

Glaucoma, Open-Angle (Phase 4)

Hypercholesterolemia (Phase 2)

Hyperlipidemias (Phase 2)

Hyperlipoproteinemias (Phase 2)

Infarction (Phase 2)

Infarction, Middle Cerebral Artery (Phase 2)

Ischemia (Phase 2)

Keratoconjunctivitis Sicca (Phase 2)

Kidney Diseases (Phase 4)

Leukemia (Phase 3)

Leukemia, Lymphoid (Phase 3)

Machado-Joseph Disease (Phase 1)

Obstetric Labor, Premature (Phase 2)

Osteoarthritis (Phase 2)

Overweight (Phase 4)

Pancreatic Fistula (Phase 2)

Pancreatic Neoplasms (Phase 2)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 3)

Premature Birth (Phase 3)

Renal Insufficiency, Chronic (Phase 4)

Schizophrenia (Phase 1)

Spinal Cord Injuries (Phase 4)

Spinocerebellar Ataxias (Phase 1)

Spinocerebellar Degenerations (Phase 1)

Thromboembolism (Phase 4)

Wounds and Injuries (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 76
  • # of Trial APIs: 83